US/UK/Canada

Share

About Us

Cantargia AB (publ), reg.no. 556791-6019, is a biotech company which is listed on Nasdaq Stockholm (ticker: CANTA). More information about Cantargia is available at http://www.cantargia.com.

Contacts

  • Cantargia AB
    Scheelevägen 27 223 63 Lund
    +46 (0)46 2756260
    http://www.cantargia.com
    • Pick a time period -
    Tags ( Active)

    Cantargia is presenting at the Biotech Showcase in San Francisco

    Cantargia AB (”Cantargia”) is presenting the company’s research and future plans at the Biotech Showcase in San Francisco, USA today, 11.00 AM local time (8.00 PM Swedish time).Biotech Showcase is an investor and networking conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and pharmaceutical executives. Biotech Showcase is of one of the industry's largest annual healthcare investor conferences and is this year hosting its eighth conference. This year the conference is expected to reach

    Cantargia strengthens management with a Vice President Cancer Research

    David Liberg has been appointed Vice President Cancer Research of Cantargia AB. Liberg has nearly twenty years of research experience within immunology and tumor biology and was graduated with a Ph.D. in immunology in 2001. Before joining Cantargia, Liberg worked at Active Biotech AB.Cantargia strengthens the organisation with David Liberg who will take up the position as VP Cancer Research at Cantargia on December 1 2015. Liberg has for the last ten years worked within pharmaceutical industry with responsibility for early research projects and activities in tumor immunology as Project

    Cantargia Interim Report for the period 1 Jan 2015 – 30 June 2015 available

    Lund, Sweden 25 August 2015 – Cantargia AB Interim Report for the second quarter 2015 is now available on the company web-site (www.cantargia.com). An extract from the report is presented below.Significant events in the second quarter of 2015 Notice of the Annual General Meeting was published on the Company’s website in April. The Annual General Meeting was held at Medicon Village on 22 May 2015 and a report from the AGM was published on the same date. At the AGM a resolution was adopted authorising the Board of Directors to decide on the issuance of new shares, on one or several

    Data on Cantargia’s antibodies in leukemia models published in international scientific journal

    Lund, Sweden 11 August 2015 – Cantargia AB (CANTA:SS) today announces that a scientific article on the use of Cantargia’s antibodies in preclinical models of acute myeloid leukemia (AML) have been published in the respected international journal Proceedings of the National Academy of Sciences of the United States of America (PNAS).The article, entitled “Antibodies targeting human IL1RAP (IL1R3) show therapeutic effects in xenograft models of acute myeloid leukemia”, was written by the research teams behind Cantargia. The article documents that Cantargia’s antibodies targeting IL1RAP have

    Cantargia and Glycotope Biotechnology signs production agreement for lead product candidate CAN04

    Lund, Sweden and Heidelberg, Germany – July 3, 2015 – Cantargia AB and Glycotope Biotechnology GmbH today announced an agreement on the production of Cantargia’s proprietary monoclonal antibody CAN04. The product candidate CAN04 is directed against the target molecule IL1RAP, expressed on cancer stem cells as well on mature cancer cells. Through the agreement, Glycotope Biotechnology will be Cantargia’s production partner to obtain material for the clinical studies of CAN04 in cancer patients.Glycotope Biotechnology will be responsible for the development and GMP (Good Manufacturing

    Cantargia licenses BioWa POTELLIGENT® Technology platform for production of lead product candidate

    Cantargia AB (CANTA:SS) and BioWa Inc. today announced that Cantargia has acquired a non-exclusive license to the POTELLIGENT® Technology platform for the production of the proprietary product candidate CAN04.  The POTELLIGENT® Technology platform has been designed for research and development of antibody dependent cellular cytotoxicity (ADCC) enhanced antibodies. Commercial details of the agreement were not disclosed.The POTELLIGENT® Technology platform will be used to produce Cantargia’s lead product candidate, the monoclonal antibody CAN04 directed against the target molecule IL1RAP. The

    Cantargia Interim Report for the period 1 Jan 2015 – 31 Mar 2015 available

    Cantargia AB interim report for first quarter 2015 is now available on the company web-site (www.cantargia.com). An extract from the report is presented below.Significant events in the first quarter of 2015In the beginning of the quarter, an extraordinary general meeting of shareholders was held, where it was decided on a public issue of units prior to a planned listing on Nasdaq First North Stockholm. The subscription period was initiated 27 January and ended 12 February 2015. Subscriptions for SEK 60 million were received, which means that the issue was 136 per cent subscribed,

    Share transaction in Cantargia AB

    Cantargia AB’s (“Cantargia”) co-founders, Professor Thoas Fioretos and Dr Marcus Järås, have sold 20 per cent of their shareholdings in the company, in accordance with their previously communicated intention and subject to the terms and conditions of their lock-up agreements.As previously communicated in Cantargia’s prospectus (published on 16 January 2015), Thoas Fioretos and Marcus Järås have, in view of their long-standing involvement in Cantargia, had the intention to sell up to 20 per cent of their shareholdings in the company. Thoas Fioretos and Marcus Järås have now sold 20 per cent

    Sunstone Capital and LU Bioscience invest 7 MSEK in Cantargia

    Cantargia, a private biopharmaceutical company developing therapeutics for the treatment of leukemia, announced earlier today that it has raised 7 MSEK. It is a joint investment by Sunstone Capital investing EUR 500,000 from its Early Engagement Program (EEP) and LUBio investing 3 MSEK.The company intends to use the capital infusion to further characterize its lead monoclonal antibody and prepare for GMP production and pre-clinical safety studies. Anki Malmborg Hager, acting CEO since February 2013, commented: “Through the capital injection we will have the opportunity to mobilize our

    There are no items matching the current filter
    There are no more items matching the current filter
    Back to top

    Subscribe

    Media